Short-chain ceramides decrease skin barrier properties

Skin Pharmacology and Physiology

Volumn 22, Issue 1, 2009, Pages 22-30

  Novotny J ^a   Janusova B ^a   Novotny M ^a   Hrabalek A ^a   Vavrova K ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Short chain ceramide analogues; Skin barrier; Sphingolipid synthesis; Stratum corneum; Structure activity relationships

Indexed keywords

CERAMIDE; CERAMIDE DERIVATIVE; INDOMETACIN; N [(1,3 DIHYDROXYDODEC 4 EN 2 YL)ACETAMIDE; N [(1,3 DIHYDROXYDODEC 4 EN 2 YL)BUTYRAMIDE; N [(1,3 DIHYDROXYDODEC 4 EN 2 YL)DODECANAMIDE; N [(1,3 DIHYDROXYDODEC 4 EN 2 YL)HEXANAMIDE; N [(1,3 DIHYDROXYDODEC 4 EN 2 YL)OCTANAMIDE; N [(1,3 DIHYDROXYOCTADEC 4 EN 2 YL)TETRACOSANAMIDE; SPHINGOLIPID; SPHINGOMYELIN; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; LIPOGENESIS; NONHUMAN; PHOSPHOLIPID MEMBRANE; PRIORITY JOURNAL; SKIN PERMEABILITY; SKIN STRUCTURE; STRATUM CORNEUM; STRUCTURE ACTIVITY RELATION; SWINE;

ANIMALS; CERAMIDES; INDOMETHACIN; MOLECULAR STRUCTURE; PERMEABILITY; SKIN; SKIN ABSORPTION; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; THEOPHYLLINE;

EID: 57649105741     PISSN: 16605527     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183923     Document Type: Article

References (45)

1. Wertz PW: Lipids and barrier function of the skin. Acta Derm Venereol Suppl (Stockh) 2000;208:7-11.
2. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M: Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 2003;42:1-36.
3. Bouwstra JA, Ponec M: The skin barrier in healthy and diseased state. Biochim Biophys Acta 2006;1758:2080-2095.
4. Wartewig S, Neubert RH: Properties of ceramides and their impact on the stratum corneum structure: a review. 1. Ceramides. Skin Pharmacol Physiol 2007;20:220-229.
5. Kessner D, Ruettinger A, Kiselev MA, Wartewig S, Neubert RH: Properties of ceramides and their impact on the stratum corneum structure. 2. Stratum corneum lipid model systems. Skin Pharmacol Physiol 2008;21:58-74.
6. Holleran WM, Takagi Y, Uchida Y: Epidermal sphingolipids: metabolism, function, and roles in skin disorders. FEBS Lett 2006;580:5456-5466.
7. Ponec M, Weerheim A, Lankhorst P, Wertz P: New acylceramide in native and reconstructed epidermis. J Invest Dermatol 2003;120:581-588.
8. Bouwstra JA, Gooris GS, Dubbelaar FE, Weerheim AM, Ijzerman AP, Ponec M: Role of ceramide 1 in the molecular organization of the stratum corneum lipids. J Lipid Res 1998;39:186-196.
9. Goñi FM, Alonso A: Biophysics of sphingolipids. 1. Membrane properties of sphingosine, ceramides and other simple sphingolipids. Biochim Biophys Acta 2006;1758:1902-1921.
10. van Blitterswijk WJ, van der Luit AH, Veldman RJ, Verheij M, Borst J: Ceramide: second messenger or modulator of membrane structure and dynamics? Biochem J 2003;369:199-211.
11. Man MQ, Feingold KR, Elias PM: Exogenous lipids influence permeability barrier recovery in acetone-treated murine skin. Arch Dermatol 1993;129:728-738.
12. Vavrova K, Zbytovska J, Palat K, Holas T, Klimentova J, Hrabalek A, Dolezal P: Ceramide analogue 14S24 ((S)-2-tetracosanoylamino-3- hydroxypropionic acid tetradecyl ester) is effective in skin barrier repair in vitro. Eur J Pharm Sci 2004;21:581-587.
13. Vavrova K, Hrabalek A, Mac-Mary S, Humbert P, Muret P: Ceramide analogue 14S24 selectively recovers perturbed human skin barrier. Br J Dermatol 2007;157:704-712.
14. Vavrova K, Hrabalek A, Dolezal P, Holas T, Zbytovska J: L-Serine and glycine based ceramide analogues as transdermal permeation enhancers: polar head size and hydrogen bonding. Bioorg Med Chem Lett 2003;13:2351-2353.
15. Vávrová K, Zbytovská J, Hrabálek A: Amphiphilic transdermal permeation enhancers: structure-activity relationships. Curr Med Chem 2005;12:2273-2291.
16. Smith EW, Maibach HI: Percutaneous Penetration Enhancers, ed 2. Boca Raton, CRC Press, 2006.
17. Kanikkannan N, Kandimalla K, Lamba SS, Singh M: Structure-activity relationship of chemical penetration enhancers in transdermal drug delivery. Curr Med Chem 2000;7:593-608.
18. Klimentova J, Kosak P, Vavrova K, Holas T, Hrabalek A: Influence of terminal branching on the transdermal permeation-enhancing activity in fatty alcohols and acids. Bioorg Med Chem 2006;14:7681-7687.
19. Thong HY, Zhai H, Maibach HI: Percutaneous penetration enhancers: an overview. Skin Pharmacol Physiol 2007;20:272-282.
20. Foss FW Jr, Snyder AH, Davis MD, Rouse M, Okusa MD, Lynch KR, Macdonald TL: Synthesis and biological evaluation of gamma-aminophosphonates as potent, subtype-selective sphingosine 1-phosphate receptor agonists and antagonists. Bioorg Med Chem 2007;15:663-677.
21. Garner P, Park JM: 1,1-Dimethylethyl (S) or (R)-4-formyl-2, 2-dimethyl-3-oxazolidinecarboxylate: a useful serinal derivative. Org Synth 1991;70:18-28.
22. Williams L, Zhang Z, Feng S, Carroll PJ, Joullié MM: Grignard reactions to chiral oxazolidine aldehydes. Tetrahedron 1996;52:11673-11694.
23. Van Overmeire I, Boldin SA, Dumont F, Van Calenbergh S, Slegers G, De Keukeleire D, Futerman AH, Herdewijn P: Effect of aromatic short-chain analogues of ceramide on axonal growth in hippocampal neurons. J Med Chem 1999;42:2697-2705.
24. Garner P, Park JM, Malecki E: A stereodivergent synthesis of D-erythro-sphingosine and D-threo-sphingosine from L-serine. J Org Chem 1988;53:4395-4398.
25. Jacobi U, Kaiser M, Toll R, Mangelsdorf S, Audring H, Otberg N, Sterry W, Lademann J: Porcine ear skin: an in vitro model for human skin. Skin Res Technol 2007;13:19-24.
26. Simonsen L, Fullerton A: Development of an in vitro skin permeation model simulating atopic dermatitis skin for the evaluation of dermatological products. Skin Pharmacol Physiol 2007;20:230-236.
27. Williams A: Alternative membranes for invitro studies; in Williams A (ed): Transdermal and Topical Drug Delivery: From Theory to Clinical Practice. London, Pharmaceutical Press, 2003, pp 54-58.
28. Andega S, Kanikkannan N, Singh M: Comparison of the effect of fatty alcohols on the permeation of melatonin between porcine and human skin. J Control Release 2001;77:17-25.
29. Simon GA, Maibach HI: The pig as an experimental animal model of percutaneous permeation in man: qualitative and quantitative observations - an overview. Skin Pharmacol Appl Skin Physiol 2000;13:229-234.
30. Franz TJ: Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol 1975;64:190-195.
31. Herold P: Synthesis of D-erythro- and D-threo- sphingosine derivatives from L-serine. Helv Chim Acta 1988;71:354-363.
32. Lapidot Y, Rappoport S, Wolman Y: Use of esters of N-hydroxysuccinimide in the synthesis of N-acylamino acids. J Lipid Res 1967;8:142-145.
33. Dhaon MK, Olsen RK, Ramasamy K: Esterification of N-protected α-amino acids with alcohol/carbodiimide/4-(dimethylamino) pyridine. Racemization of aspartic and glutamic acid derivatives. J Org Chem 1982;47:1962-1965.
34. Chen H, Mendelsohn R, Rerek ME, Moore DJ: Fourier transform infrared spectroscopy and differential scanning calorimetry studies of fatty acid homogeneous ceramide 2. Biochim Biophys Acta 2000;1468:293-303.
35. Yoshiike T, Aikawa Y, Sindhvananda J, Suto H, Nishimura K, Kawamoto T, Ogawa H: Skin barrier defect in atopic dermatitis: increased permeability of the stratum corneum using dimethyl sulfoxide and theophylline. J Dermatol Sci 1993;5:92-96.
36. Karlsson KA: On the character and functions of sphingolipids. Acta Biochim Pol 1998;45:429-438.
37. Pascher I: Molecular arrangements in sphingolipids. Conformation and hydrogen bonding of ceramide and their implication on membrane stability and permeability. Biochim Biophys Acta 1976;455:433-451.
38. Li L, Tang X, Taylor KG, DuPre DB, Yappert MC: Conformational characterization of ceramides by nuclear magnetic resonance spectroscopy. Biophys J 2002;82:2067-2080.
39. Rerek ME, Chen H, Markovic B, Van Wyck D, Garidel P, Mendelsohn R, Moore DJ: Phytosphingosine and sphingosine ceramide headgroup hydrogen bonding: structural insights through thermotropic hydrogen/deuterium exchange. J Phys Chem B 2001;105:9355-9362.
40. Ongpipattanakul B, Burnette RR, Potts RO, Francoeur ML: Evidence that oleic acid exists in a separate phase within stratum corneum lipids. Pharm Res 1991;8:350-354.
41. Nybond S, Bjorkqvist YJ, Ramstedt B, Slotte JP: Acyl chain length affects ceramide action on sterol/sphingomyelin-rich domains. Biochim Biophys Acta 2005;1718:61-66.
42. Megha, Sawatzki P, Kolter T, Bittman R, London E: Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts). Biochim Biophys Acta 2007;1768:2205-2212.
43. Chiantia S, Kahya N, Schwille P: Raft domain reorganization driven by short- and long-chain ceramide: a combined AFM and FCS study. Langmuir 2007;23:7659-7665.
44. Gidwani A, Brown HA, Holowka D, Baird B: Disruption of lipid order by short-chain ceramides correlates with inhibition of phospholipase D and downstream signaling by FcepsilonRI. J Cell Sci 2003;116:3177-3187.
45. Shabbits JA, Mayer LD: Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 2003;1612:98-106.